SEC Company Response from ReShape Lifesciences Inc. (RSLS) (CIK 0001427570) (HIND) — Oct 3, 2016
ReShape Lifesciences Inc. (RSLS) (CIK 0001427570)
Date: Oct. 3, 2016 · CIK: 0001427570 · Accession: 0001193125-16-729072
AI Filing Summary & Sentiment
File numbers found in text: 333-213551
Letter
Re: Obalon Therapeutics, Inc.
October 3, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1 (File No. 333-213551)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Obalon Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective Wednesday, October 5, 2016, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable.
In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from September 26, 2016 to the date of this letter, we have effected approximately the following distribution of copies of the preliminary prospectus, dated September 26, 2016:
To Whom Distributed
Number of Copies
Institutions, Brokers and Other
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[signature page follows]
Very truly yours,
UBS SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP October 3, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Obalon Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-213551) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters (the “Underwriters”), hereby join in the request of Obalon Therapeutics, Inc. with respect to the effective time of the above-referenced Registration Statement so that it will become effective Wednesday, October 5, 2016, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. In connection with this acceleration request and pursuant to Rule 460 under the Act, please be advised that, during the period from September 26, 2016 to the date of this letter, we have effected approximately the following distribution of copies of the preliminary prospectus, dated September 26, 2016: To Whom Distributed Number of Copies Institutions, Brokers and Other 1948 We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating Underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [signature page follows] Very truly yours, UBS SECURITIES LLC CANACCORD GENUITY INC. STIFEL, NICOLAUS & COMPANY, INCORPORATED on behalf of themselves and as representatives of the Underwriters UBS SECURITIES LLC By: /s/ John Hagens Name: John Hagens Title: Executive Director By: /s/ Evan Demcoe Name: Evan Demcoe Title: Associate Director CANACCORD GENUITY INC. By: /s/ Jeffrey G. Barlow Name: Jeffrey G. Barlow Title: President, Canaccord Genuity Inc. (U.S.) STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Keith Lister Name: Keith Lister Title: Managing Director [Signature Page to Underwriters’ Acceleration Request Letter]